The Filing Desk

Krystal Biotech vs Tarsus Pharmaceuticals

Krystal Biotech KRYS · Tarsus Pharmaceuticals TARS · Biotechnology

Tarsus Pharmaceuticals reported revenue of $451 million in fiscal 2025, 1.2 times Krystal Biotech's $389 million in fiscal 2025. Krystal Biotech's revenue grew 33.9% in its latest year, and Tarsus Pharmaceuticals' grew 146.7%. Krystal Biotech had an operating margin of 41.5%, against -15.7% at Tarsus Pharmaceuticals. Free cash flow was $189 million at Krystal Biotech and −$22 million at Tarsus Pharmaceuticals.

Side by side

Krystal BiotechTarsus Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$389M$451M
Revenue growth33.9%146.7%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin41.5%−15.7%
Net margin52.6%−14.7%
Free cash flow$189M−$22M
Free cash flow margin48.5%−4.9%
Return on capital43.6%—
Net debt to EBITDA−5.0x—
Dividends and buybacks$0M$0M
Change in diluted share count0.7%11.1%
Last close$305.23$80.28
P/E at the last close41.4×—
Insider trades, last 12 monthssold $105.3 millionsold $20.0 million
Piotroski F-score5 of 84 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Krystal BiotechTarsus Pharmaceuticals
Operating margin
Percent of revenue
Krystal BiotechTarsus Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Krystal BiotechTarsus Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Krystal Biotech and Tarsus Pharmaceuticals pages.